HSR25-172: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin
Roles
Author
Document Type
Article
Publication Date
1-1-2025
Publication Title
Journal of the National Comprehensive Cancer Network
DOI
10.6004/jnccn.2024.7314
Recommended Citation
Hattin, R., Aboaid, H., Hussain, A., Schauer, S., Schlesinger, T., Twells, R., Aharonian, K., Parto, R., Rahmani, R., Lambert-Swainston, C., Jones, D. T., Srinvasmurthy, R., Thein, K. Z., & Htut, T. W. (2025). HSR25-172: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin. Journal of the National Comprehensive Cancer Network, 23 (3.5), Article HSR25-172. https://doi.org/10.6004/jnccn.2024.7314
